Addex Therapeutics Competitors and Similar CompaniesClear all

Addex Therapeutics's competitors and similar companies include Dizlin, Genentech, Mankind Pharma and Cipla.

	Addex Therapeutics Addex Therapeutics, a development-stage biopharmaceutical company, discovers small-molecule pharmaceutical products.	Dizlin Dizlin Pharmaceuticals is a pharmaceutical research company developing treatments for Parkinson's disease.	Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.	Mankind Pharma Mankind Pharma is a pharmaceutical company developing, commercializing, and delivering medicines.	Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.
Founding Date	Founding Date 2002	Founding Date 2003	Founding Date 1976	Founding Date 1995	Founding Date 1935
Type	Type Public	Type Private	Type Subsidiary	Type Private	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare clinical research drug development pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Plan-les-Ouates, CH HQ San Francisco, US	Locations Göteborg, SE HQ	Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more	Locations New Delhi, IN HQ	Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more
Employees	Employees 23	Employees 6	Employees 18,077	Employees 16,2532% increase	Employees 27,764
Financial
Revenue (est.)	Revenue (est.) CHF404k (FY, 2024)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ₹277.1b (FY, 2026)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods ₹95.5b (FY, 2026)
Gross profit	Gross profit CHF449k (FY, 2024)	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit ₹195b (FY, 2026)
Net income	Net income (CHF6.9m) (FY, 2024)	Net income N/A	Net income N/A	Net income N/A	Net income ₹38.7b (FY, 2026)
Funding
Total funding raised	Total funding raised $ 94.7m	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 239m	Total funding raised N/A